NASDAQ:INGN - Inogen Stock Price, Forecast & News

Inogen's stock was trading at $40.61 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, INGN shares have increased by 23.3% and is now trading at $50.06. View which stocks have been mosted impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Inogen.

Inogen is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Inogen.

Inogen Inc (NASDAQ:INGN) announced its quarterly earnings data on Tuesday, February, 25th. The medical technology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by $0.17. The medical technology company had revenue of $78.92 million for the quarter, compared to analyst estimates of $90.11 million. Inogen had a net margin of 5.79% and a return on equity of 7.07%. Inogen's revenue was down 8.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.44 earnings per share. View Inogen's earnings history.

Inogen updated its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $385-400 million, compared to the consensus revenue estimate of $403.47 million.

6 analysts have issued 1-year price targets for Inogen's shares. Their forecasts range from $45.00 to $90.00. On average, they expect Inogen's stock price to reach $62.00 in the next twelve months. This suggests a possible upside of 23.9% from the stock's current price. View analysts' price targets for Inogen.

Media coverage about INGN stock has been trending negative on Sunday, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Inogen earned a news impact score of -2.0 on InfoTrie's scale. They also gave news articles about the medical technology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutInogen.

Inogen saw a drop in short interest in February. As of February 28th, there was short interest totaling 2,380,000 shares, a drop of 6.3% from the February 13th total of 2,540,000 shares. Based on an average trading volume of 352,500 shares, the days-to-cover ratio is currently 6.8 days. Approximately 13.1% of the shares of the stock are short sold. View Inogen's Current Options Chain.

Some companies that are related to Inogen include MSA Safety (MSA), Wright Medical Group (WMGI), Wound Management Technologies (WNDM), Avanos Medical (AVNS), Establishment Labs (ESTA), Invacare (IVC), RTI Surgical (RTIX), Lakeland Industries (LAKE), Sientra (SIEN), Allied Healthcare Products (AHPI), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Histogenics (HSGX), NanoVibronix (NAOV) and Bionik Laboratories (BNKL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), NVIDIA (NVDA), First Solar (FSLR), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU) and Square (SQ).

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Inogen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Fred Alger Management LLC (4.44%), AQR Capital Management LLC (3.92%), State Street Corp (3.00%), New York State Common Retirement Fund (2.25%), Norges Bank (1.83%) and Rockefeller Capital Management L.P. (1.28%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View institutional ownership trends for Inogen.

INGN stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Renaissance Technologies LLC, Cubist Systematic Strategies LLC, UBS Asset Management Americas Inc., State Street Corp, Marshall Wace LLP, American International Group Inc., and AlphaCrest Capital Management LLC. View insider buying and selling activity for Inogen.

INGN stock was acquired by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, Norges Bank, Point72 Asset Management L.P., Beacon Investment Advisory Services Inc., Tamarack Advisers LP, Great West Life Assurance Co. Can, Jane Street Group LLC, and Pinebridge Investments L.P.. Company insiders that have bought Inogen stock in the last two years include Heath Lukatch, and Loren L Mcfarland. View insider buying and selling activity for Inogen.

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INGN stock can currently be purchased for approximately $50.06.

Inogen has a market capitalization of $1.10 billion and generates $361.94 million in revenue each year. The medical technology company earns $20.95 million in net income (profit) each year or $1.07 on an earnings per share basis. Inogen employs 1,020 workers across the globe. View additional information about Inogen.

The official website for Inogen is http://www.inogen.com/.

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]